摘要
A recent study by Zoufaly et al.published in The Lancet Respiratory Medicine describes encouraging data from the first severe COVID-19 patient successfully treated with human recombinant soluble angiotensin-converting enzyme-2(hrsACE2).1 The published data document upon treatment of an adaptive immune response,the disappearance of the virus swiftly from the serum,the nasal cavity and lungs,and a reduction of inflammatory cytokine levels that are critical for COVID-19 pathology.Notably,the use of hrsACE2 did not impede the generation of neutralizing antibodies,leading to a significant clinical improvement of the treated patient.
